Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

FDA 510(k)

LYMPHOCYTE TYPING, NEGATIVE CONTROL

K-Number: K761008 · 1977-04-06

ApplicantHyland Therapeutic Div., Travenol Laboratories
Decision Date1977-04-06
Product CodeLGO
Advisory CommitteeHE
DecisionSubstantially Equivalent

Device Summary

LYMPHOCYTE TYPING, NEGATIVE CONTROL is the device name listed in this FDA 510(k) record. The listed applicant is Hyland Therapeutic Div., Travenol Laboratories. It received FDA 510(k) clearance on 1977-04-06 under 510(k) number K761008. The device is classified under product code LGO. It was reviewed by the HE advisory panel. FDA Decision: Substantially Equivalent.

Frequently Asked Questions

What is the LYMPHOCYTE TYPING, NEGATIVE CONTROL?

LYMPHOCYTE TYPING, NEGATIVE CONTROL is a medical device that received FDA 510(k) clearance on 1977-04-06. The listed applicant is Hyland Therapeutic Div., Travenol Laboratories. The 510(k) number is K761008.

When did LYMPHOCYTE TYPING, NEGATIVE CONTROL receive FDA 510(k) clearance?

LYMPHOCYTE TYPING, NEGATIVE CONTROL received FDA 510(k) clearance on 1977-04-06, under 510(k) number K761008.

Who is the listed applicant for LYMPHOCYTE TYPING, NEGATIVE CONTROL?

The FDA 510(k) record lists Hyland Therapeutic Div., Travenol Laboratories as the applicant. This does not by itself establish the device manufacturer.

What is the FDA product code for LYMPHOCYTE TYPING, NEGATIVE CONTROL?

The FDA product code for LYMPHOCYTE TYPING, NEGATIVE CONTROL is LGO.

Related Clinical Trials

Related records are matched automatically using names, product codes, or other metadata. A match does not establish a verified clinical, scientific, corporate, or regulatory relationship; review the linked official sources.

NCT07608549FLASH Pilot Phase 1 Safety StudyNOT_YET_RECRUITINGNCT06562205PAP Systems External Clinical Studies (ECS)NOT_YET_RECRUITINGNCT06443177The Effect of Sympathetic Modulation on Cerebral Vasospasm Secondary to Aneurysmal Subarachnoid HemorrhageSUSPENDEDNCT07095751Artificial Intelligence-assisted Uro-Cam Catheter Assessment System for Diagnosing Bladder CancerNOT_YET_RECRUITING

Other records listing Hyland Therapeutic Div., Travenol Laboratories as applicant

Related records are matched automatically using names, product codes, or other metadata. A match does not establish a verified clinical, scientific, corporate, or regulatory relationship; review the linked official sources.

K820835ALUMINA SILICA-ACTIVATED PARTIAL THROMK820192HAEMOPHILUS INFLUENZAE TYPE B ANTISERUMK812220NEPHELOMETRIC SOLID TURBIDITY STANDARDK810078Q-PAK THERAPEUTIC DRUG MONIT. CONTROL SK810077OMEGA THERAPEUTIC DRUG MONIT. CONTROL S.K802610ALERT A,HDL-APOLIPOROTEIN A, TEST KIT

View all 44 devices →

Related Devices (Code: LGO)

Related records are matched automatically using names, product codes, or other metadata. A match does not establish a verified clinical, scientific, corporate, or regulatory relationship; review the linked official sources.

K894947PLATELIA TOXO IGG KITKallestad Diag, A Div. of Erbamont, Inc.K874544SNAP(R) CAMPYLOBACTER CULTURE IDENT DIAGNOSTIC KITMolecular Biosystems, Inc.K791118HLA CONTROL SERACalbiochem-Behring Corp.K761009LYMPHOCYTE TYPING, POSITIVE CONTROLHyland Therapeutic Div., Travenol Laboratories

Official Source

View on FDA Database →

Data sourced from FDA Open API. For the most current and authoritative information, always refer to the official record.

↑